Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Treatment of older adults with newly diagnosed FLT3-mutated AML: focus on lower-intensity triplet regimens.
Journal: Expert review of hematology
Published: August 19, 2026
Incidence, Prevalence, and Survival Outcomes of Patients with Myeloproliferative Neoplasms in the United States: a SEER database analysis, years 2000-2021.
Journal: Research square
Published: May 18, 2026
Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.
Journal: Journal of hematology & oncology
Published: March 25, 2026
Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.
Journal: American journal of hematology
Published: February 01, 2026
Cytomolecular Mechanisms of Relapse and Post-Relapse Outcomes After Frontline FLT3 Inhibitor-Based Therapy in FLT3 -Mutated AML.
Journal: American journal of hematology
Published: June 28, 2025
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 18, 2025
Investigational drugs in early phase trials for myelofibrosis.
Journal: Expert opinion on investigational drugs
Published: November 28, 2024
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma.
Journal: Blood advances
Published: November 07, 2024
Last Updated: 09/26/2026